Randomised, Controlled Study to Assess Safety and Tolerance of Infant Formula With Prebiotics and Postbiotics in Healthy Infants.
WAVE
A Randomised, Controlled, Double-blind, Parallel Group, Multi-country Study to Investigate the Safety and Tolerance of Infant Formula With Prebiotics and Postbiotics in Healthy Term Infants.
1 other identifier
interventional
279
1 country
1
Brief Summary
A randomised, controlled, double-blind, parallel group, multi-country study to investigate the safety and tolerance of infant formula with prebiotics and postbiotics in healthy term infants.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2019
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 4, 2019
CompletedFirst Posted
Study publicly available on registry
July 10, 2019
CompletedStudy Start
First participant enrolled
July 10, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 3, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 3, 2021
CompletedDecember 17, 2021
December 1, 2021
2.4 years
July 4, 2019
December 16, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Weight gain
from baseline until the age of 17 weeks (test product versus control product). Weight gain will be calculated as weight (in grams) at visit minus weight at baseline divided by the number of days.
17 weeks
Study Arms (2)
Test product
EXPERIMENTALCow's milk based infant formula containing prebiotics and postbiotics
Control product
ACTIVE COMPARATORCow's milk based infant formula without prebiotics and postbiotics
Interventions
Eligibility Criteria
You may qualify if:
- \. Healthy, singleton, term infants (gestational age ≥37 weeks + 0 days and ≤41weeks + 6 days);
- \. Infants with age at screening ≤14 days;
- \. Birth weight within 10th to 90th percentile per gestational age and sex, according to Intergrowth Standards;
- \. Head circumference at screening within ±2 SD per age and sex according to WHO Child Growth Standards;
- \. a Randomised groups: Infants who are exclusively formula fed and/or whose mothers have autonomously decided to exclusively formula feed, i.e. not to breastfeed or have ended breastfeeding before screening, and who are intending to exclusively formula feed at least till their infant is 17 weeks of age; OR b Breastfed reference group: Infants who are exclusively breastfed and whose mothers are intending to exclusively breastfeed at least till their infant is 17 weeks of age;
- \. Written informed consent from parent(s) and/or legal guardian(s) aged ≥18 years at screening.
You may not qualify if:
- \. Randomised groups: Infants who require a special diet other than non-hydrolysed, cow's milk based infant formula (e.g. due to known or suspected to have cow's milk allergy, soy allergy and/or lactose intolerance);
- \. Infants with current or previous illnesses/conditions and/or known or suspected congenital diseases or malformations which could interfere with the study or its outcome parameters, such as but not limited to: GI malformations, congenital metabolic disorders, severe congenital cardiac disorders, immunodeficiency or major surgery, as per the clinical judgement of the Investigator;
- \. Infants with previous, current or intended participation in any other clinical study involving investigational or marketed products;
- \. Incapability of infants' parents to comply with study protocol as per the judgement of the Investigator;
- \. Infants born from mothers known to have (any) hepatitis or human immunodeficiency virus;
- \. Infants born from mothers with significant medical conditions during pregnancy that might interfere with the study or its outcome parameters or known to affect intra-uterine growth (e.g. placenta previa, pre-eclampsia, eclampsia, Type 1, 2 diabetes) as per clinical judgement of the Investigator;
- \. Infants born from mothers, who did participate in any clinical study involving investigational products during pregnancy, and for infants in Breastfed reference group: mothers who are currently participating or intend to participate in any clinical study involving investigational products during lactation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Poliklinika Ginekologiczno-Położnicza Sp. z o.o. Sp. k.
Bialystok, 15-435, Poland
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 4, 2019
First Posted
July 10, 2019
Study Start
July 10, 2019
Primary Completion
December 3, 2021
Study Completion
December 3, 2021
Last Updated
December 17, 2021
Record last verified: 2021-12